Hepatitis B Virus Surface Antibody, Qualitative/Quantitative, Serum
Use
This test is used for identifying previous exposure to hepatitis B virus and determining adequate immunity from hepatitis B vaccination. It evaluates post-vaccination immunity status or post-acute infection status of hepatitis B virus. A positive result indicates recovery from hepatitis B virus (HBV) infection or acquired immunity from HBV vaccination. Anti-HBs levels of 10.0 mIU/mL or greater indicate adequate immunity.
Special Instructions
Not provided.
Limitations
This assay is not licensed by the US FDA for screening of blood, plasma, and tissue donors. Performance characteristics have not been established for use in determining susceptibility to HBV infection in infants, children, or adolescents. False-positive results can occur due to passive transfer from recent blood component therapy. Results from different assay methods may not be interchangeable.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ECLIA)
Biomarkers
HBs Antibody
Protein
LOINC Codes
- 5193-8 - HBV surface Ab SerPl IA-aCnc
- 10900-9 - HBV surface Ab Ser Ql IA
- 5193-8 - HBV surface Ab SerPl IA-aCnc
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.7 mL
Minimum Volume
0.6 mL
Container
Serum gel (red-top tubes are not acceptable); Submission Container: Plastic vial
Collection Instructions
Centrifuge blood collection tube per manufacturer's instructions and aliquot serum into a plastic vial within 2 hours of collection.
Patient Preparation
For 24 hours before specimen collection, patient should not take multivitamins or dietary supplements containing biotin (vitamin B7).
Causes for Rejection
Gross hemolysis, lipemia, icterus, heat-inactivated specimen
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 6 days |
| Frozen | 90 days |